4 active not recruiting. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 4 |
| Phase 1 | 2 | Active not recruiting 2 |
Follow plerixafor: new trials by email Literature Review of plerixafor trials Research Report on plerixafor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia TBI, Hydroxyurea, briquilimab - Sickle Cell Anemia, Beta Thalassemia | Phase 1 / Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 40 | 2022-05-12 | 2026-03-12 |
| Reduced Intensity Transplantation for Severe Sickle Cell Disease hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus, hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus - Sickle Cell Disease | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 46 | 2020-04-30 | 2026-09-01 |
| Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) leukapheresis, Plerixafor, carmustine, etoposide, cytarabine, melphalan - Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 59 | 2015-10-01 | 2026-10-30 |
| Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Filgrastim, Genetically Engineered Lymphocyte Therapy - Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 8 | 2011-10-20 | 2026-09-11 |
Anemia, Sickle Cell (2) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · beta-Thalassemia (1)
City of Hope Medical Center (1) · Memorial Sloan Kettering Cancer Center (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · St. Jude Children's Research Hospital (1)
United States (4)
Akshay Sharma, MBBS (1) · Elizabeth L Budde, MD,PhD (1) · John F Tisdale, M.D. (1) · Sergio Giralt, MD (1)
PMID 27118452, PMID 34515338, PMID 38691679
P30CA033572 (1), P50CA107399 (1)